SCHEMBL8320028

SCHEMBL8320028

Fc1cccc(-c2c[nH]c3ncc(-c4ccccc4)cc23)c1

nearest known ligand 0.78

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
AXL P30530 7/20 0.78
CDK8 P49336 3/20 0.78
TNIK Q9UKE5 1/20 0.78
KIT P10721 3/20 0.68
SGK1 O00141 1/20 0.66
CDC7 O00311 1/20 0.66
ROCK2 O75116 1/20 0.66
MAP4K4 O95819 1/20 0.66
PIM1 P11309 1/20 0.66
PRKACA P17612 1/20 0.66
CDK2 P24941 1/20 0.66
GSK3B P49841 1/20 0.66
HIPK2 Q9H2X6 1/20 0.66
CLK4 Q9HAZ1 1/20 0.66
IRAK4 Q9NWZ3 1/20 0.66
NTRK1 P04629 1/20 0.65
IGF1R P08069 1/20 0.64
RIPK1 Q13546 1/20 0.64
MAP3K11 Q16584 1/20 0.63

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8320989 0.89 AXL (0.83) AXLCDK8TNIKKITSGK1
SCHEMBL8941685 0.88 AXL (1.00) AXLCDK8TNIKSGK1ROCK2
SCHEMBL12763289 0.87 KIT (0.66) AXLCDK8TNIKKITCDC7
SCHEMBL17319205 0.87 KIT (0.69) AXLCDK8TNIKKITCDC7
SCHEMBL8320902 0.86 MAPK8 (0.67) AXLCDK8TNIKKITSGK1
SCHEMBL29337149 0.84 NTRK1 (0.90) AXLCDK8TNIKKITSGK1
SCHEMBL12572765 0.84 AXL (0.76) AXLCDK8TNIKKITSGK1
SCHEMBL1857492 0.84 AXL (0.76) AXLCDK8TNIKKITSGK1
SCHEMBL3761281 0.84 AXL (0.76) AXLCDK8TNIKKITSGK1
SCHEMBL17319207 0.84 KIT (0.69) AXLCDK8TNIKKITSGK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090215771-A1 JNK INHIBITORS GRACZYK PIOTR 2009-08-27 US disclosed
US-20090215771-A1 JNK INHIBITORS GRACZYK PIOTR 2009-08-27 US disclosed
US-7432375-B2 JNK inhibitors EISAI R & D MANAGEMENT CO., LTD. (JP) 2008-10-07 US disclosed
US-7432375-B2 JNK inhibitors EISAI R & D MANAGEMENT CO., LTD. (JP) 2008-10-07 US disclosed
WO-2004078756-A2 JNK INHIBITORS EISAI CO., LTD. (JP) 2004-09-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090215771-A1 JNK INHIBITORS MAPKAPK2, MAPK1, MAPKAPK3 AXL 3999/4885CDK8 360/4885TNIK 215/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.